0001384101-20-000033.txt : 20200303
0001384101-20-000033.hdr.sgml : 20200303
20200303175547
ACCESSION NUMBER: 0001384101-20-000033
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200228
FILED AS OF DATE: 20200303
DATE AS OF CHANGE: 20200303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kennedy Giulia C
CENTRAL INDEX KEY: 0001769333
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36156
FILM NUMBER: 20684334
MAIL ADDRESS:
STREET 1: 338 MAIN STREET #26E
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94105
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERACYTE, INC.
CENTRAL INDEX KEY: 0001384101
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 205455398
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 243-6300
MAIL ADDRESS:
STREET 1: 6000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: CALDEROME INC
DATE OF NAME CHANGE: 20061219
4
1
wf-form4_158327613077235.xml
FORM 4
X0306
4
2020-02-28
0
0001384101
VERACYTE, INC.
VCYT
0001769333
Kennedy Giulia C
6000 SHORELINE COURT
SUITE 300
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Scientific & Med Officer
Common Stock
2020-02-28
4
A
0
12000
0
A
100018
D
Common Stock
2020-03-02
4
F
0
896
0
D
99122
D
Stock Option (right to buy)
24.69
2020-02-28
4
A
0
70000
0
A
2030-03-27
Common Stock
70000.0
70000
D
Restricted stock units awarded on February 28, 2020 vest 25% on March 2, 2021 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.
Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes.
The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
/s/ Keith Kennedy as attorney-in-fact
2020-03-03